Literature DB >> 12625415

The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.

Takahisa Hirose1, Ryuzo Mizuno, Takahiko Yoshimoto.   

Abstract

This study was designed to determine the effect of a novel insulin secretagogue, nateglinide, on the glycemic response curve and early insulin secretion following oral glucose load in impaired glucose tolerance (IGT) subjects. Thirteen subjects were given a 75 g oral glucose tolerance test (75 g OGTT), the findings of which resulted in the diagnosis of IGT. The subjects returned to our hospital immediately. Eight subjects, in whom neither body weight nor life style (daily diet and exercise) was significantly altered during this period, were given 90 mg of nateglinide 5 min before a second oral glucose load in order to examine restoration of impaired early insulin secretion. Nateglinide administration resulted in the almost normalization of the glycemic response curve with restoration of impairment in early insulin response at 30 and 60 min after an oral glucose load. The area under the secreted insulin-time curve was not changed significantly by nateglinide administration. A single dose of nateglinide was shown to almost normalize the glycemic response curve after a 75 g OGTT and to restore impairment in early insulin response in IGT subjects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12625415     DOI: 10.1507/endocrj.49.649

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook.

Authors:  Olivia M Farr; Christos S Mantzoros
Journal:  Metabolism       Date:  2017-01-04       Impact factor: 8.694

Review 2.  Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David Peick Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

Review 3.  Diabetes in Japan.

Authors:  Takahisa Hirose; Ryuzo Kawamori
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

4.  Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.

Authors:  Kyoko Kudo-Fujimaki; Takahisa Hirose; Tomoaki Yoshihara; Fumihiko Sato; Yuki Someya; Chie Ohmura; Akio Kanazawa; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2013-11-05       Impact factor: 4.232

5.  Effects of glucose load and nateglinide intervention on endothelial function and oxidative stress.

Authors:  Leilei Wang; Lixin Guo; Lina Zhang; Yan Zhou; Qinghua He; Zheng Zhang; Meng Wang
Journal:  J Diabetes Res       Date:  2013-04-07       Impact factor: 4.011

Review 6.  A review of nateglinide in the management of patients with type 2 diabetes.

Authors:  Nicholas Tentolouris; Christina Voulgari; Nicholas Katsilambros
Journal:  Vasc Health Risk Manag       Date:  2007

7.  Ingestion of an exogenous ketone monoester improves the glycemic response during oral glucose tolerance test in individuals with impaired glucose tolerance: A cross-over randomized trial.

Authors:  Takashi Nakagata; Yoshifumi Tamura; Hideyoshi Kaga; Motonori Sato; Nozomu Yamasaki; Yuki Someya; Satoshi Kadowaki; Daisuke Sugimoto; Hiroaki Satoh; Ryuzo Kawamori; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2020-11-01       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.